Scotland's Postcode Lottery: Patients Face Unequal Access to Vital New Medicines

A new report from the Association of the British Pharmaceutical Industry (ABPI), released today, reveals that Scottish patients face a significant 'postcode lottery' when trying to access the latest approved medicines. This groundbreaking study highlights major differences in prescribing rates for crucial treatments like GLP-1 medicines for diabetes and weight management, and non-statin cholesterol drugs, creating an 'unwarranted variation' across NHS Scotland 14 health boards. These disparities, which saw some areas prescribing GLP-1 medicines at rates nearly ten times higher than others, cannot be fully explained by differing patient needs alone, according to the ABPI. The report, supported by analytics firm LCP Health, points to 'avoidable barriers' and local service organization as key culprits, with some medicines taking over a year to be added to local formularies despite a national 90-day expectation. This mirrors earlier concerns raised by First Minister John Swinney, who recently announced plans to reshape NHS Scotland by consolidating its 14 territorial health boards into two strategic ones, aiming to reduce long waiting times and improve equitable access. The ABPI has issued seven recommendations, urging the Scottish Government and NHS Scotland to collaborate more closely, advocating for earlier planning, greater transparency in formulary decisions, and piloting protected funding for high-impact medicines. This 'triple helix approach' involving government, health services, and industry is crucial to ensure that national approvals from the Scottish Medicines Consortium (SMC) translate into tangible benefits for patients, no matter where they live in Scotland. The coming months will show if these systemic reforms can truly close the widening access gap.